Illumina Inc

Day range

$267.55 – $274.00

Open

$269.69

Prev close

$269.42

Volume

602.79K

Market cap

$40.68B

Shares out

151M

P/E

49.31

P/S

9.05

P/B

14.33

P/FCF

43.70

ROE

29.1%

ROA

12.4%

Debt/Equity

0.70

Div yield

0.00%

As of Oct 23, 2026

• Underwriting agreementOct 13, 2026

  Initially, three commercial paper dealers will each act as a dealer under the CP Program pursuant to the terms and conditions of a commercial paper dealer agreement entered into among the Company and each Dealer. Each Dealer Agreement provides the terms under which the applicable Dealer will either purchase the CP Notes from the Company or arrange for the sale of the CP Notes by the Company to one or more purchasers.

• Debt retirementAug 17, 2026

  Illumina expects to use the net proceeds from the offering, together with cash on hand, to repay its 4.650% notes due September 9, 2026, of which $500 million aggregate principal amount was outstanding as of June 28, 2026.

• Deal terminationAug 13, 2026

  The commitments under the Credit Agreement replace, in their entirety, the commitments under the Credit Agreement dated as of January 4, 2023. The Existing Credit Agreement and the commitments thereunder were terminated as of August 13, 2026.

• Underwriting agreementAug 12, 2026

  Illumina entered into an Underwriting Agreement with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein, for the issuance and sale by Illumina of $300,000,000 aggregate principal amount of its 4.950% notes due 2029.

• Settlement agreementAug 7, 2026

  Effective August 21, 2025, Illumina, Inc. (the "Company") entered into a Release Agreement with the plaintiffs and all named defendants reflecting the terms of the settlement of the litigation captioned Icahn Partners LP, et al., v. Francis DeSouza, et al., C.A. No. 2023-1045-PAF (the "Action") in the Court of Chancery of the State of Delaware (the "Court"), relating to the Company's acquisition of GRAIL, Inc. The Release Agreement provides that, in exchange for mutual releases but no payment by any party, this Action shall be dismissed with prejudice as to the Plaintiffs only and without prejudice to any other Illumina stockholders.

• TMOThermo Fisher Scientific, Inc.+1.06%
• QGENQIAGEN N.V.-0.06%

Days to cover

1.6

Short interest

9.47M

Avg volume

5.8M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?
  neutralThe Motley Fool· Oct 25, 2026
• Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
  positiveZacks Investment Research· Oct 22, 2026
• How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
  positiveZacks Investment Research· Oct 20, 2026
• Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth
  positiveGlobeNewswire Inc.· Oct 20, 2026
• Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
  positiveZacks Investment Research· Oct 16, 2026